The prospects of anti-rabies vaccine in developing countries: A Review

Abstract

Background: Rabies is a recognized viral zoonosis, and it continues to pose a significant public health threat, mainly in developing nations. It is the most common viral disease in
tropical humans, but it is enzootic globally. Despite the fact that it is completely avoidable, it is estimated to cause at least 55,000 annual deaths in most developing countries due to a lack of adequate therapy and mitigation steps. Only immunization can effectively control, prevent, and eradicate rabies in humans and animals. Despite attempts in developing countries since 1919 to develop and manufacture anti-rabies vaccines for human and animal protection against rabies, effective management and prophylaxis through vaccination has been hindered by a lack of modern technology and infrastructure needed for the development and manufacture of safe and effective vaccines.
Aim: Thıs review was desıgned to highlight Anti-rabies vaccine prospects in developing countries.
Method: We reviewed publications from internet sources and searched for appropriate documents available in English. Which included Medline, Google scholar and Ajol.
Results: We highlighted the Anti-Rabies Vaccine alternatives, such as Monoclonal antibody RVC20 and adaptation of Vero cell lines for rabies vaccine productionwhich can be used in developing countries, based on our online reviews.
Conclusion: It would be difficult for developing countries to meet the economic demand for the manufacture of a rabies vaccine using recombinant DNA technology. As a result,
the use of the Vero cell line should be embraced.